Agomab Therapeutics (AGMB) CMO lists vested stock option grants

Rhea-AI Filing Summary

Agomab Therapeutics NV Chief Medical Officer Philippe Constantin Wiesel reported his initial holdings of stock options on the company’s common shares. The filing lists ten option grants with exercise prices between $0.0005 and $14.26, expiring from 2029 through 2036. Footnotes explain which grants are already fully vested and which vest over time, and note that each American Depositary Share currently represents one common share.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wiesel Philippe Constantin

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

BELGIUM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Agomab Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	03/14/2029	Common shares(2)	21,732	$1.13(3)	D
Stock Option (Right to Buy)	(1)	10/09/2029	Common shares(2)	15,000	$1.13(3)	D
Stock Option (Right to Buy)	(1)	04/17/2030	Common shares(2)	11,992	$1.13(3)	D
Stock Option (Right to Buy)	(1)	10/30/2030	Common shares(2)	23,983	$1.13(3)	D
Stock Option (Right to Buy)	(1)	03/05/2031	Common shares(2)	155,433	$0.0005(3)	D
Stock Option (Right to Buy)	(1)	06/28/2032	Common shares(2)	30,520	$0.0005(3)	D
Stock Option (Right to Buy)	(1)	10/10/2033	Common shares(2)	87,641	$0.0005(3)	D
Stock Option (Right to Buy)	(4)	07/08/2034	Common shares(2)	6,927	$2.81(3)	D
Stock Option (Right to Buy)	(4)	11/04/2034	Common shares(2)	140,758	$3.42(3)	D
Stock Option (Right to Buy)	(5)	01/15/2036	Common shares(2)	133,789	$14.26(3)	D

Explanation of Responses:

1. The shares underlying this option are fully vested and exercisable.

2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

4. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

5. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ellen Lefever, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Philippe Constantin Wiesel report in his Agomab (AGMB) Form 3?

Philippe Constantin Wiesel reports his initial holdings of stock options on Agomab Therapeutics common shares. The Form 3 lists ten direct option grants, detailing exercise prices, expiration dates, and vesting status as his baseline derivative position as Chief Medical Officer.

What stock option exercise prices are disclosed for the Agomab (AGMB) CMO?

The filing shows stock option exercise prices on Agomab common shares ranging from $0.0005 to $14.26. These prices are reported in U.S. dollars after converting from euros at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

How do the Agomab (AGMB) CMO’s option grants vest according to the Form 3?

Some options are fully vested and exercisable, while others follow schedules. One grant vested 50% on February 9, 2026, with the rest vesting in 24 equal monthly installments. Another vests 25% on February 9, 2027, with the balance vesting in 36 monthly installments.

What are the expiration dates of the Agomab (AGMB) CMO’s reported stock options?

The Chief Medical Officer’s stock options on Agomab common shares carry expiration dates between 2029 and 2036. Individual grants expire on specific dates such as March 14, 2029, October 9, 2029, and January 15, 2036, defining the periods during which they can be exercised.

How many underlying common shares are covered by individual Agomab (AGMB) option grants?

Each option grant covers a stated number of underlying common shares, such as 21,732, 15,000, 155,433, 87,641, 140,758, and 133,789 shares. These figures describe the maximum number of common shares that could be acquired upon exercising each respective option grant.

How are Agomab (AGMB) common shares represented by American Depositary Shares?

The Form 3 notes that Agomab’s common shares may be represented by American Depositary Shares. Each American Depositary Share currently represents one common share, so the underlying share counts for the reported options translate directly into the same number of ADS on a one-for-one basis.